MCID: URN010
MIFTS: 54

Urinary Tract Obstruction

Categories: Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Urinary Tract Obstruction

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 11 14 16 71 75
Obstructive Uropathy 11 53 14
Urinary Obstruction 11
Urologic Diseases 71

Classifications:



External Ids:

Disease Ontology 11 DOID:5200
ICD9CM 34 599.6
NCIt 49 C79805
SNOMED-CT 68 7163005
ICD10 31 N13.9
UMLS 71 C0042075 C0178879

Summaries for Urinary Tract Obstruction

MalaCards based summary: Urinary Tract Obstruction, also known as obstructive uropathy, is related to congenital anomalies of kidney and urinary tract 2 and obstructive nephropathy, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is BNC2 (Basonuclin 2), and among its related pathways/superpathways are Epithelial to mesenchymal transition in colorectal cancer and Cell adhesion_ECM remodeling. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Urinary tract obstruction is a urologic disease consisting of a decrease in the free passage of urine... more...

Related Diseases for Urinary Tract Obstruction

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)
# Related Disease Score Top Affiliating Genes
1 congenital anomalies of kidney and urinary tract 2 32.3 UMOD REN LCN2 HAVCR1 AQP2
2 obstructive nephropathy 31.8 SMAD3 SMAD2 REN LCN2 HAVCR1 FN1
3 oligohydramnios 31.6 REN CRP ALB
4 urethral stricture 31.5 KLK3 CRP CCN2
5 hydronephrosis 31.3 REN NAGLU MIR192 LCN2 KLK3 HAVCR1
6 neurogenic bladder 31.1 KLK3 CRP ALB
7 urinary tract infection 31.1 UMOD REN LCN2 KLK3 HAVCR1 CRP
8 aortic aneurysm 31.0 SMAD3 SMAD2 REN CRP ALB
9 chronic pyelonephritis 31.0 UMOD REN CRP B2M ALB
10 cystitis 31.0 UMOD HBEGF CRP CDH1
11 urolithiasis 30.9 UMOD CDH1 ALB
12 aortic aneurysm, familial abdominal, 1 30.8 REN MIR199A1 LCN2 FN1 CRP ALB
13 acute kidney failure 30.8 UMOD REN LCN2 HAVCR1 B2M ALB
14 chronic kidney disease 30.8 UMOD REN LCN2 CRP CCN2 B2M
15 cakut 30.8 UMOD REN GDNF AQP2
16 renal hypertension 30.8 REN FN1 CRP ALB
17 actinomycosis 30.8 CRP ALB
18 ureterolithiasis 30.8 KLK3 CRP ALB
19 pyelonephritis 30.8 UMOD NAGLU LCN2 CRP AQP2 ALB
20 urogenital tuberculosis 30.8 KLK3 CRP ALB
21 pericardial effusion 30.7 REN CRP ALB
22 preterm premature rupture of the membranes 30.7 MIR199A1 FN1 CRP
23 compartment syndrome 30.7 LCN2 CRP ALB
24 anuria 30.7 REN LCN2 HAVCR1 CRP ALB
25 uremia 30.7 REN CRP B2M ALB
26 appendicitis 30.7 LCN2 CRP ALB
27 bowel dysfunction 30.7 LCN2 CRP ALB
28 vesicoureteral reflux 30.6 UMOD REN NAGLU LCN2 HAVCR1 GDNF
29 kidney papillary necrosis 30.6 UMOD REN HAVCR1 AQP2 ALB
30 peritonitis 30.6 LCN2 CRP B2M ALB
31 pelvic inflammatory disease 30.6 LCN2 CRP CDH1
32 hyperuricemia 30.6 UMOD REN LCN2 HAVCR1 CRP ALB
33 respiratory failure 30.6 REN MIR199A1 CRP ALB
34 urinary system disease 30.6 UMOD REN NAGLU MIR199A1 MIR192 KLK3
35 wilms tumor 1 30.5 REN MIR199A1 CDH1 CCN2 ALB
36 prostatic hypertrophy 30.5 KLK3 CRP ALB
37 bacteriuria 30.5 UMOD CRP ALB
38 lymphocele 30.5 KLK3 ALB
39 urethritis 30.5 KLK3 CRP ALB
40 hypertensive retinopathy 30.5 REN CRP ALB
41 deficiency anemia 30.5 REN FN1 CRP B2M ALB
42 necrotizing fasciitis 30.5 FN1 CRP ALB
43 cardiac tamponade 30.5 REN CRP ALB
44 renal tubular acidosis 30.5 REN B2M AQP2
45 diabetes mellitus, ketosis-prone 30.5 REN CRP ALB
46 clear cell adenocarcinoma 30.5 SMAD3 SMAD2 KLK3
47 kidney disease 30.5 UMOD SMAD3 REN NAGLU MIR199A1 LCN2
48 cystic kidney disease 30.5 UMOD REN MIR199A1 LCN2 HAVCR1 CRP
49 inguinal hernia 30.5 NAGLU KLK3 CRP ALB
50 renal tuberculosis 30.4 REN CRP B2M ALB

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Chronic Kidney Disease Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hydronephrosis
Kidney Disease Nephrolithiasis, X-Linked Recessive, with Renal Failure
Paralytic Ileus Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Prostatitis Protein-Energy Malnutrition
Ureterolithiasis Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction

Symptoms & Phenotypes for Urinary Tract Obstruction

UMLS symptoms related to Urinary Tract Obstruction:


dysuria; polyuria; urgency of micturition; other and unspecified genitourinary symptoms; renal colic; pain in urethra; uti symptoms; urethral burning on micturition; loin pain; ureteral pain; flank tenderness; difficulty passing urine; urinary tenesmus; burning urination; bladder discomfort; renal pain; urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ALB AQP2 B2M CCN2 CDH1 CRP
2 growth/size/body region MP:0005378 10.24 AQP2 B2M BNC2 CCN2 CDH1 FN1
3 cardiovascular system MP:0005385 10.13 ALB B2M CCN2 CDH1 CRP FN1
4 renal/urinary system MP:0005367 10.11 ALB AQP2 GDNF LCN2 MIR192 NAGLU
5 liver/biliary system MP:0005370 10.03 ALB B2M CCN2 FN1 LCN2 NAGLU
6 immune system MP:0005387 9.97 ALB B2M CDH1 CRP FN1 GDNF
7 digestive/alimentary MP:0005381 9.92 ALB B2M BNC2 CCN2 CDH1 GDNF
8 mortality/aging MP:0010768 9.86 ALB AQP2 B2M BNC2 CCN2 CDH1
9 integument MP:0010771 9.28 AQP2 B2M CCN2 CDH1 FN1 HBEGF

Drugs & Therapeutics for Urinary Tract Obstruction

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
6
Sennosides Experimental Phase 4 517-43-1
7
Uric acid Investigational Phase 4 69-93-2 1175
8 Polyethylene glycol 3350 Phase 4
9 Senna Phase 4
10 Folate Phase 4
11 Vitamin B9 Phase 4
12 Vitamin B Complex Phase 4
13 Vitamins Phase 4
14 Trace Elements Phase 4
15 Hematinics Phase 4
16 Micronutrients Phase 4
17 Anesthetics, Local Phase 4
18 Narcotics Phase 4
19 Analgesics, Opioid Phase 4
20
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
21
Mirabegron Approved Phase 3 223673-61-8 18319735 9865528
22
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971
23
Lomefloxacin Approved, Investigational Phase 3 98079-51-7 3948
24
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
25
Ofloxacin Approved Phase 3 82419-36-1 4583
26
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
27
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
28
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
29 Analgesics Phase 3
30 Adrenergic beta-Agonists Phase 3
31 Adrenergic beta-3 Receptor Agonists Phase 3
32 Adrenergic Agonists Phase 3
33 Adrenergic Agents Phase 3
34
Solifenacin Succinate Phase 3 242478-38-2 216457
35 Muscarinic Antagonists Phase 3
36 Cholinergic Antagonists Phase 3
37 Cholinergic Agents Phase 3
38 Anti-Anxiety Agents Phase 3
39 calcium channel blockers Phase 3
40 Anti-Infective Agents Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 3
42 Parasympatholytics Phase 3
43 Sodium Potassium Chloride Symporter Inhibitors Phase 3
44 diuretics Phase 3
45
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
46
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
47
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
48
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
49
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
50 Neurotransmitter Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Optimizing Pain Control in Transurethral Resection of the Prostate Unknown status NCT04102566 Phase 4 Ibuprofen 600 mg
2 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
3 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Completed NCT02805504 Phase 4 Exparel;Marcaine
4 A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures Recruiting NCT04826484 Phase 4 Exparel 133 miligrams per 10 milliliter injection;Bupivacaine Hydrochloride
5 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Withdrawn NCT03591289 Phase 4 NMB with rocuronium bromide
6 Uroflowmetry Parameter (Delta Q Value) as a Noninvasive Tool to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction Completed NCT05359484 Phase 2, Phase 3
7 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
8 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Completed NCT03927781 Phase 3 Pregabalin 300mg
9 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
10 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
11 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
12 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
13 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
14 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
15 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
16 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
17 The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction Recruiting NCT04972890 Phase 2, Phase 3
18 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
19 Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP) Not yet recruiting NCT05620784 Phase 3 Furosemide
20 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
21 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
22 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
23 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
24 Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention Completed NCT04555343 Phase 1, Phase 2 Tranexamic acid
25 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Completed NCT03081858 Phase 1, Phase 2 TSD-001
26 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Completed NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
27 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
28 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
29 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Completed NCT03562897 Phase 2
30 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Terminated NCT04387448 Phase 2 GFB-887;Placebo
31 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
32 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Terminated NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
33 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Terminated NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
34 An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Terminated NCT04950114 Phase 2 GFB-887
35 Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy Withdrawn NCT02961114 Phase 1, Phase 2
36 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects Completed NCT02052713 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
37 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects Completed NCT02058576 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
38 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01232010 Phase 1 Mirodenafil
39 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01231997 Phase 1 Udenafil
40 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
41 Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study Recruiting NCT04731376 Phase 1 Testosterone Cypionate
42 Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions Not yet recruiting NCT03899298 Phase 1
43 A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral Not yet recruiting NCT03258658 Phase 1
44 Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora Not yet recruiting NCT03463239 Phase 1
45 A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02386111 Phase 1 Combination of varlilumab and sunitinib
46 A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer Terminated NCT02543645 Phase 1 Combination of Varlilumab and Atezolizumab
47 Influence of Diuresis Timing (F+0 Vs F-15) on 99m Tc DTPA Renography for the Diagnosis of Suspected Obstructive Uropathy in Adult Hydronephrotic Patients. Unknown status NCT04564469 Furosemide
48 Staged Ureteroscopy After Initial Urinary Drainage Versus Direct Ureteroscopy in the Treatment of Pediatric Obstructive Calcular Anuria Unknown status NCT02139059
49 Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis Unknown status NCT04594161
50 GreenLight (532nm) LASER (XPS) Enucleation vs. Thulium LASER Enucleation of Prostate for Treatment of Benign Prostatic Hyperplasia Unknown status NCT03305861

Search NIH Clinical Center for Urinary Tract Obstruction

Genetic Tests for Urinary Tract Obstruction

Anatomical Context for Urinary Tract Obstruction

Organs/tissues related to Urinary Tract Obstruction:

MalaCards : Prostate, Kidney, Brain, Bone Marrow, Cervix, Spinal Cord, Smooth Muscle

Publications for Urinary Tract Obstruction

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 5360)
# Title Authors PMID Year
1
Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP. 53 62
18342929 2008
2
[Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency]. 53 62
18254226 2007
3
New paradigms for advanced prostate cancer. 53 62
17554403 2007
4
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. 53 62
15017212 2004
5
Glial cell line derived neurotrophic factor is expressed by epithelia of human renal dysplasia. 53 62
12441997 2002
6
[Urinary enzyme excretion in childhood uropathy]. 53 62
12434629 2002
7
[Urinary excretion of Tamm-Horsfall protein, albumin and beta-2 microglobulin in children with recurrent urinary tract infection]. 53 62
11579828 2001
8
[Screening for early detection of prostate cancer (first experience in Israel)]. 53 62
11242898 2001
9
Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. 53 62
10576204 1999
10
Clinical pharmacokinetics and pharmacodynamics of finasteride. 53 62
8846625 1996
11
Tamm-Horsfall protein: are serum levels a marker for urinary tract obstruction? 53 62
7696106 1994
12
[Evaluation of renal function and prediction of renal functional recovery in children with unilateral hydronephrosis using renal pelvic urine]. 53 62
1282579 1992
13
Atypical presentation of focal xanthogranulomatous pyelonephritis. 62
36439935 2023
14
Intense 68 Ga-Pentixafor Activity in Idiopathic Retroperitoneal Fibrosis. 62
36026598 2022
15
Palliative urinary diversion in patients with malignant ureteric obstruction due to gynaecological cancer. 62
31018967 2022
16
Severe Bilateral Hydroureteronephrosis Due to Chronic Obstructive Uropathy. 62
36413454 2022
17
Fetal therapy of LUTO (lower urinary tract obstruction) - a follow-up observational study. 62
34652254 2022
18
Xanthogranulomatous Pyelonephritis - A Diagnostic and Therapeutic Dilemma. 62
36473546 2022
19
Obstetric outcomes after fetal intervention - a single-center descriptive review. 62
36411675 2022
20
A case study of pyelolymphatic backflow demonstrated on CT. 62
36189162 2022
21
Current material engineering strategies to prevent catheter encrustation in urinary tracts. 62
36118951 2022
22
A Rare Co-association of Autoimmune Thyroiditis and Idiopathic Retroperitoneal Fibrosis. 62
36465222 2022
23
Complex vesical diverticulum, an unusual cause of obstructive uropathy. 62
36062205 2022
24
Prenatal Detection of Vesico-Allantoic Cyst: Ultrasound and Autopsy Findings. 62
36369825 2022
25
Pediatric urolithiasis: what can pediatricians expect from radiologists? 62
36329164 2022
26
Duplex renal collecting system presenting with hydroureteronephrosis following pelvic organ prolapse and sacrocolpopexy in an adult female. 62
36033162 2022
27
Fetal Megacystis in the first trimester: Comparing management and outcomes between longitudinal bladder length groups. 62
36372362 2022
28
Prenatally Diagnosed Posterior Urethral Valves: Ethical Dilemmas of Fetal Intervention. 62
35680050 2022
29
Prostate primary intravascular large B-cell lymphoma: A case report. 62
36386016 2022
30
The Effects of TRPC6 Knockout in Animal Models of Kidney Disease. 62
36421724 2022
31
Preputial urethrostomy with preservation of the local anatomy in 4 dogs. 62
36069396 2022
32
Non dilated obstructive uropathy secondary to tur-syndrome in patient with solitary kidney. 62
36267342 2022
33
The Case | An 80-year-old man with obstructive uropathy. 62
36272748 2022
34
Interventions for obstructive uropathy in advanced prostate cancer: a population-based study. 62
35485254 2022
35
Identifying Common Molecular Mechanisms in Experimental and Human Acute Kidney Injury. 62
36402654 2022
36
Verapamil inhibited the development of ureteral stricture by blocking CaMK II-mediated STAT3 and Smad3/JunD pathways. 62
35922702 2022
37
Selective angioembolization as a management strategy for angiomyolipoma causing urinary tract obstruction. 62
36199836 2022
38
Clues for the early loss of renal function in congenital hydronephrosis: Analysis of renal pelvis collagen ratio, diuresis renography and upper urinary tract morphology. 62
36464563 2022
39
Effect of Endovascular Treatment on Urinary Obstruction Caused by Iliac Artery Aneurysm: A Case Series and Review of the Literature. 62
35926787 2022
40
CT features of malignant tubular genital tract tumors in seven goats. 62
36383072 2022
41
Lower urinary tract obstruction caused by fibroepithelial polyp in a newborn boy. 62
36016721 2022
42
Abdominal Evisceration: A Rare Complication of In Utero Vesicoamniotic Shunting. 62
35623499 2022
43
Bilateral Renal Artery Thrombosis: A Case of Successful Kidney Recovery After Prolonged Anuria. 62
36381786 2022
44
Congenital anterior urethral valves and diverticula. 62
36376124 2022
45
The importance of CT Urography in early diagnosis of anatomical variations in urogenital tract: case presentation. 62
36039085 2022
46
Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. 62
36282399 2022
47
Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis. 62
36374823 2022
48
Stone disease in low- and middle-income countries: could augmented reality have a role in its management? 62
35993671 2022
49
Multiple pyonephrotic compartments with different microorganisms and an infected "calcium milk" in a patient with bilateral obstructive uropathy: A challenging case. 62
36126458 2022
50
Acute and Late Adverse Effects of Prostate-Only or Pelvic Stereotactic Radiation Therapy in Prostate Cancer: A Comparative Study. 62
35724773 2022

Variations for Urinary Tract Obstruction

Expression for Urinary Tract Obstruction

Search GEO for disease gene expression data for Urinary Tract Obstruction.

Pathways for Urinary Tract Obstruction

GO Terms for Urinary Tract Obstruction

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 ALB B2M CCN2 CDH1 CRP FN1
2 extracellular space GO:0005615 9.7 UMOD REN MIR199A1 MIR192 LCN2 KLK3
3 SMAD protein complex GO:0071141 9.46 SMAD3 SMAD2

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SMAD protein complex assembly GO:0007183 9.56 SMAD3 SMAD2
2 ureteric bud development GO:0001657 9.55 SMAD3 SMAD2 GDNF
3 regulation of binding GO:0051098 9.26 SMAD3 SMAD2
4 paraxial mesoderm morphogenesis GO:0048340 8.92 SMAD3 SMAD2

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enterobactin binding GO:1903981 8.92 LCN2 ALB

Sources for Urinary Tract Obstruction

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....